Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793553093> ?p ?o ?g. }
- W2793553093 endingPage "235" @default.
- W2793553093 startingPage "225" @default.
- W2793553093 abstract "Malignant melanoma is an important type of cancer worldwide due to its aggressiveness and poor survival rate. Significant efforts to understand the biology of melanoma and approaches to treat the advanced disease are focused on targeted gene inhibitors. Frequently mutated genes, such as NRAS, B-RAF and TP53, significantly exceed the frequency of mutations of other genes, emphasizing their importance for future targeted therapies. Considering the antitumor activity of benzothiazolic derivatives, this study aimed to demonstrate the action of benzothiazolic (E)-2-((2-(benzo[d]thiazol-2-yl)hydrazono)methyl)-4-nitrophenol (AFN01) against three established human melanoma cell lines that recapitulate the molecular landscape of the disease in terms of its genetic alterations and mutations, such as the TP53, NRAS and B-RAF genes. The results presented here indicate that AFN01, as a significant cytostatic and cytotoxic drug due to its induction of DNA fragmentation, causes single and double DNA strand breaks, consequently inhibiting cell proliferation, migration and invasion by promoting apoptosis. Our data suggest that AFN01 might be considered as a future therapeutic option for managing melanoma." @default.
- W2793553093 created "2018-03-29" @default.
- W2793553093 creator A5006136258 @default.
- W2793553093 creator A5008082390 @default.
- W2793553093 creator A5008630972 @default.
- W2793553093 creator A5009622751 @default.
- W2793553093 creator A5023179948 @default.
- W2793553093 creator A5029609119 @default.
- W2793553093 creator A5044019950 @default.
- W2793553093 creator A5057523816 @default.
- W2793553093 creator A5069115459 @default.
- W2793553093 creator A5085557494 @default.
- W2793553093 creator A5086720905 @default.
- W2793553093 date "2018-08-01" @default.
- W2793553093 modified "2023-10-01" @default.
- W2793553093 title "Anticancer potential of benzothiazolic derivative (E)-2-((2-(benzo[d]thiazol-2-yl)hydrazono)methyl)-4-nitrophenol against melanoma cells" @default.
- W2793553093 cites W1556583010 @default.
- W2793553093 cites W1570494660 @default.
- W2793553093 cites W1595856931 @default.
- W2793553093 cites W1825812833 @default.
- W2793553093 cites W1935819037 @default.
- W2793553093 cites W1964098656 @default.
- W2793553093 cites W1970082148 @default.
- W2793553093 cites W1974325263 @default.
- W2793553093 cites W1993929814 @default.
- W2793553093 cites W1997312624 @default.
- W2793553093 cites W2000241906 @default.
- W2793553093 cites W2026235754 @default.
- W2793553093 cites W2032463878 @default.
- W2793553093 cites W2034882416 @default.
- W2793553093 cites W2040914101 @default.
- W2793553093 cites W2049642475 @default.
- W2793553093 cites W2052781279 @default.
- W2793553093 cites W2054593373 @default.
- W2793553093 cites W2055298771 @default.
- W2793553093 cites W2055600273 @default.
- W2793553093 cites W2060121584 @default.
- W2793553093 cites W2060498658 @default.
- W2793553093 cites W2074283564 @default.
- W2793553093 cites W2079852484 @default.
- W2793553093 cites W2092549818 @default.
- W2793553093 cites W2092629964 @default.
- W2793553093 cites W2095501114 @default.
- W2793553093 cites W2099606391 @default.
- W2793553093 cites W2100592123 @default.
- W2793553093 cites W2110500210 @default.
- W2793553093 cites W2130765442 @default.
- W2793553093 cites W2132221327 @default.
- W2793553093 cites W2143152083 @default.
- W2793553093 cites W2144963939 @default.
- W2793553093 cites W2150980053 @default.
- W2793553093 cites W2153105757 @default.
- W2793553093 cites W2161080185 @default.
- W2793553093 cites W2210624024 @default.
- W2793553093 cites W2283250967 @default.
- W2793553093 cites W2317841482 @default.
- W2793553093 cites W2412960951 @default.
- W2793553093 cites W2509205885 @default.
- W2793553093 cites W2528672236 @default.
- W2793553093 cites W2557256009 @default.
- W2793553093 cites W2618479889 @default.
- W2793553093 cites W2950699317 @default.
- W2793553093 cites W915033202 @default.
- W2793553093 doi "https://doi.org/10.1016/j.tiv.2018.03.001" @default.
- W2793553093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29574239" @default.
- W2793553093 hasPublicationYear "2018" @default.
- W2793553093 type Work @default.
- W2793553093 sameAs 2793553093 @default.
- W2793553093 citedByCount "10" @default.
- W2793553093 countsByYear W27935530932018 @default.
- W2793553093 countsByYear W27935530932020 @default.
- W2793553093 countsByYear W27935530932021 @default.
- W2793553093 countsByYear W27935530932022 @default.
- W2793553093 countsByYear W27935530932023 @default.
- W2793553093 crossrefType "journal-article" @default.
- W2793553093 hasAuthorship W2793553093A5006136258 @default.
- W2793553093 hasAuthorship W2793553093A5008082390 @default.
- W2793553093 hasAuthorship W2793553093A5008630972 @default.
- W2793553093 hasAuthorship W2793553093A5009622751 @default.
- W2793553093 hasAuthorship W2793553093A5023179948 @default.
- W2793553093 hasAuthorship W2793553093A5029609119 @default.
- W2793553093 hasAuthorship W2793553093A5044019950 @default.
- W2793553093 hasAuthorship W2793553093A5057523816 @default.
- W2793553093 hasAuthorship W2793553093A5069115459 @default.
- W2793553093 hasAuthorship W2793553093A5085557494 @default.
- W2793553093 hasAuthorship W2793553093A5086720905 @default.
- W2793553093 hasBestOaLocation W27935530931 @default.
- W2793553093 hasConcept C104317684 @default.
- W2793553093 hasConcept C154317977 @default.
- W2793553093 hasConcept C185592680 @default.
- W2793553093 hasConcept C190283241 @default.
- W2793553093 hasConcept C202751555 @default.
- W2793553093 hasConcept C21790070 @default.
- W2793553093 hasConcept C2777658100 @default.
- W2793553093 hasConcept C2781187634 @default.
- W2793553093 hasConcept C501734568 @default.
- W2793553093 hasConcept C502942594 @default.
- W2793553093 hasConcept C54355233 @default.